U.S. Department of Health and Human Services
This section summarizes key updates to the NIH COVID-19 Treatment Guidelines. These updates include additions to the clinical spectrum of infection, prevention and prophylaxis, antithrombotic therapy, a statement on the emergency use authorization (EUA) of baricitinib, therapeutic management of patients, and a statement on the emergency use authorization (EUA) of casirivimab plus imdevimab combination for the treatment of non-hospitalized patients with mild to moderate COVID-19 who are at high risk for progressing to severe disease and/or hospitalization.
- Click on the PDF link below to access this section.
- Return to this page. Click “Next” below access the next section.
- The last section provides a link to the quiz, registration, payment, and certificate.